Roche Holding AG (RHHBY) on Monday announced positive data from Phase 3 Portal study, a long-term extension of the Phase III Archway study, of Susvimo for the treatment of people with neovascular age-related macular degeneration (nAMD).
Results showed that with two refills a year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in about 95% of patients.
The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.